Nephrocare Health Services Share Price

In Continuation to our letter dated October 21, 2026 please find enclosed link of the audio recording of the Investors'' Conference Call held on November 04, 2026 on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026

• BSE India
• 1 week ago

Please find attached monitoring agency report for the quarter ended September 30, 2026.

• BSE India
• 1 week 1 day ago

<h3><span style="font-size:16px;"><strong>Healthcare Services company Nephrocare Health Services announced Q2FY27 results</strong></span></h3> <p><strong>Standalone Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAICRAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="nGwIHf_1k"> <li data-complete="true" data-hveid="CAAICRAB" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_1l"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_1n">Revenue from operations:<!--TgQPHd|||[]--></strong> Stood at Rs 1,765.79 million for Q2FY27, up 3.64% QoQ from Rs 1,703.78 million in Q1FY27 and increasing by 13.25% YoY against Rs 1,559.20 million in Q2FY26. For H1FY27, revenue reached Rs 3,469.57 million, showing a YoY growth of 13.85% over Rs 3,047.46 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_1t"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_1v">Total income:<!--TgQPHd|||[]--></strong> Arrived at Rs 1,826.62 million for Q2FY27, expanding by 3.49% QoQ from Rs 1,765.02 million in Q1FY27 and up 15.04% YoY compared to Rs 1,587.85 million in Q2FY26. For H1FY27, standalone total income expanded to Rs 3,590.86 million, up 15.62% YoY from Rs 3,105.83 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAH" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_21"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_23">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> Reached Rs 169.11 million for Q2FY27, tracking a sequential rise of 1.31% QoQ over Rs 166.93 million in Q1FY27 and reversing a PBT loss of Rs 306.17 million in Q2FY26. For H1FY27, standalone PBT turned positive at Rs 336.04 million, compared to a loss of Rs 237.19 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAK" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_29"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_2b">Profit after tax (PAT):<!--TgQPHd|||[]--></strong> Reached Rs 143.08 million for Q2FY27, reporting a growth of 13.89% QoQ from Rs 125.63 million in Q1FY27 and achieving a positive reversal against a PAT loss of Rs 324.14 million in Q2FY26. For H1FY27, standalone PAT stood at Rs 268.71 million against a net loss of Rs 274.00 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAN" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_2h"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_2j">Earnings per equity share (EPS):<!--TgQPHd|||[]--></strong> Basic standalone EPS for Q2FY27 was Rs 1.42, showing a sequential enhancement of 13.60% QoQ over Rs 1.25 in Q1FY27 and bouncing back from a negative EPS of Rs 3.82 in Q2FY26. For H1FY27, basic EPS was positive at Rs 2.68 compared to an EPS loss of Rs 3.26 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Consolidated Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAICxAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="nGwIHf_2z"> <li data-complete="true" data-hveid="CAAICxAB" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_30"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_32">Revenue from operations:<!--TgQPHd|||[]--></strong> Recorded at Rs 3,033.98 million for Q2FY27, demonstrating an increase of 7.68% QoQ from Rs 2,817.54 million in Q1FY27 and scaling up by 23.47% YoY over Rs 2,457.18 million in Q2FY26. For H1FY27, consolidated operational revenue stood at Rs 5,851.52 million, up 23.58% YoY against Rs 4,735.01 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICxAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_33"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_35">Total income:<!--TgQPHd|||[]--></strong> Achieved Rs 3,113.95 million for Q2FY27, marking an increase of 7.67% QoQ relative to Rs 2,892.13 million in Q1FY27 and a growth of 24.75% YoY against Rs 2,496.07 million in Q2FY26. For H1FY27, consolidated total income accumulated to Rs 6,002.93 million, gaining 24.04% YoY over Rs 4,839.66 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICxAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_36"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_38">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> For Q2FY27, PBT was reported at Rs 404.12 million, falling marginally by 1.51% QoQ against Rs 410.30 million in Q1FY27 but showing a total recovery against a consolidated PBT loss of Rs 6.24 million in Q2FY26. For H1FY27, consolidated PBT expanded by 191.98% YoY to Rs 814.42 million from Rs 278.93 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICxAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_39"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_3b">Profit after tax (PAT):<!--TgQPHd|||[]--></strong> Stood at Rs 335.31 million for Q2FY27, which indicates a QoQ growth of 4.87% over Rs 319.74 million in Q1FY27 and tracks a turnaround from a consolidated net loss of Rs 94.74 million in Q2FY26. For H1FY27, consolidated PAT stood at Rs 655.05 million, increasing by 360.39% YoY compared to Rs 142.28 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICxAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_3c"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_3e">Earnings per equity share (EPS):<!--TgQPHd|||[]--></strong> Basic consolidated EPS came in at Rs 3.34 for Q2FY27, pointing up by 4.70% QoQ over Rs 3.19 in Q1FY27 and recovering from an EPS loss of Rs 1.12 in Q2FY26. For H1FY27, basic consolidated EPS stood at Rs 6.52, expanding YoY by 285.80% over Rs 1.69 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><br /> <!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_3s">Segment-wise Performance:</strong><!--TgQPHd|||[]--></p> <ul data-complete="true" data-hveid="CAAIDRAC" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="nGwIHf_3u"> <li data-complete="true" data-hveid="CAAIDRAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_3v"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_3x">India:<!--TgQPHd|||[]--></strong> Contributed Rs 1,608.81 million to consolidated revenue in Q2FY27, increasing by 3.54% QoQ from Rs 1,553.79 million in Q1FY27 and growing 10.91% YoY over Rs 1,450.56 million in Q2FY26. For H1FY27, revenue from India totaled Rs 3,162.60 million.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_3y"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_40">Philippines:<!--TgQPHd|||[]--></strong> Brought in Rs 1,047.17 million during Q2FY27, representing a QoQ jump of 15.54% against Rs 906.29 million in Q1FY27 and a YoY expansion of 36.52% compared to Rs 767.04 million in Q2FY26. For H1FY27, Philippines operations registered revenue of Rs 1,953.46 million.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_41"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_43">Uzbekistan:<!--TgQPHd|||[]--></strong> Disclosed revenue of Rs 333.67 million for Q2FY27, up 3.84% QoQ from Rs 321.34 million in Q1FY27 and rising by 39.63% YoY from Rs 238.96 million in Q2FY26. For H1FY27, Uzbekistan operations contributed Rs 655.01 million.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAG" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="nGwIHf_44"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="nGwIHf_46">Others:<!--TgQPHd|||[]--></strong> Generated Rs 44.33 million in Q2FY27, compared to Rs 36.12 million in Q1FY27 and Rs 0.62 million in Q2FY26. For H1FY27, other geographical regions generated Rs 80.45 million.</li> </ul> <p><strong>Vikram Vuppala, Chairman & MD, said:</strong> “The dialysis market across the World continues to grow due to the increasing burden of Diabetes and hypertension, as well as improving access due to various interventions. NephroPlus continues to grow healthily in India and international markets and expect margins to remain in a healthy range.</p> <p>We are excited to open NephroPlus in Kazakhstan, which will be our 6th market. The two clinics we acquired are a good starting point for us to better understand the local market nuances before we start scaling this network in Kazakhstan.</p> <p>We have technically qualified in the Saudi Arabia’s Ministry of Health tender. We are one of the 12 Providers who qualified to bid for 4 regions in this tender and hence expect the process to be very competitive.</p> <p>We continue to invest in Strategic initiatives to strengthen our Platform over the long term. One major initiative is that we recently launched a new NIDA initiative – NephroPlus International Dialysis Academy. We intend to train lot of nurses from the Philippines and India to enable us to expand in International markets.”</p> <p><strong>Rohit Singh, Group Chief Executive Officer, said:</strong> “H1FY27 took NephroPlus into a sixth country, with our network now at 570 clinics across 6 countries. Revenue grew 23.6% YoY to Rs 585.2 crore and Adjusted EBITDA rose 15.3% to Rs 134.4 crore. We delivered over 21 lakh treatments, up 12.6% YoY, with guest volumes up 9.6%. Growth came from a combination of new market entries, acquisitions and steady volumes across our established networks.</p> <p>Kazakhstan is our newest market, entered through the acquisition of 2 clinics with 34 machines in Almaty, giving us a base from which to assess the wider Central Asian opportunity. In the Philippines, 10 acquisitions during the half took our network there to 55 clinics. In Saudi Arabia, our Riyadh clinic is now operational and home dialysis has commenced in both Riyadh and Jeddah.</p> <p>Clinically, we are piloting Peritoneal Dialysis in Punjab, with nearly 50 guests onboarded. We have also begun centre-level analysis of the barriers keeping guests on twice-weekly sessions and of earlier vascular access, both of which bear directly on guest survival.</p> <p>On technology, automated off-hours calling now gathers guest feedback and speeds up query resolution, while in-house agents are compressing our development and quality assurance cycles so improvements reach guests sooner. Expansion is only as good as the care it carries.”</p> <p><strong>Prashant Goenka, Chief Financial Officer, added:</strong> “Our India platform keeps delivering, and it continues to carry us across borders into new countries. International business is now 47% of our revenue. In H1FY27, revenue grew 23.6% YoY, beating our 15–20% guidance, as we have every single quarter. Adjusted EBITDA grew 15.3%, and Adjusted PAT grew 34.7%.</p> <p>We are investing with discipline. In H1FY27, we spent Rs 102 crore on capex, adding 40 clinics in India and 11 in the Philippines, and we opened in two new countries, Saudi Arabia and Kazakhstan. That gives us more ways to grow. We converted 69% of our EBITDA into cash, and with more than Rs 500 crore in liquidity, we have the resources to fund our plans and the confidence to meet our guidance.</p> <p>As we enter new markets, margins and returns will move during the ramp-up. That's the nature of building something new. But they will stay healthy, because our goal is clear: a scalable global dialysis platform built for the long term.”</p> <p><a class="lb" href="/get-document/post/pdf/5927073/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 week 1 day ago